Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Ascendis Pharma A/S

CUSIP: 04351P901 | 10 institutional holders

Quarters

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile